Group items tagged

The Department of Health and Social Care (DHSC) today (19 October) issued its official response to an evaluation conducted by an independent expert panel from the Health and Social Care Committee (HSCC) regarding government commitments in the pharmacy sector. The joint agreement between DHSC, NHSE, and CPE (Community Pharmacy England) under a five-year plan commitment to review the funding model, however, the current status is "continue to monitor and discuss progress". The government has claimed that the panel's rating has "not been met" and still "requires improvement". However, the funding "remains subject to affordability and consultation with the sector on the activity that can be delivered within that funding envelope".

The National Pharmacy Association (NPA), released survey data today (30 October) which suggests Britons have a higher regard for community pharmacies than retail settings. It also highlighted the level of awareness of pharmacies' healthcare duties, which range from NHS medicines consultations to monitoring blood pressure. The survey conducted by Research Without Barriers involved 1680 adults in England from 20-23 October 2023. The data showed that over 90 per cent of adults in England are aware that pharmacies offer each of these services. The survey also suggested that 56 per cent of respondents find it appropriate to ask their local pharmacies for help to quit smoking, and 63 per cent would ask for a blood pressure check.

Pharmacy owners using NHS Business Services Authority (NHSBSA) Manage Your Service (MYS) portal are urged to complete the 2023/24 Community Pharmacy Assurance Framework (CPAF) screening questionnaire which is available until midnight on Sunday (30 July). The short screening questionnaire consists of 10 questions. Those who are not yet signed up to MYS will be able to complete the questionnaire online. The questions will be published on the NHSBSA website shortly. Once the screening questionnaires have been completed, NHS England will then select a small number of pharmacies for a monitoring visit and/or to complete the full CPAF questionnaire. Community Pharmacy England has published a short Briefing on the screening process. As the questions have not changed since 2022/23 the previous briefing is still relevant.

Acknowledging the ongoing challenges in delivering the required IT systems for the scheduled launch of the Pharmacy First service on January 31, NHS England reported progress in fulfilling 'many' commitments outlined in its plan to enhance primary care access during a board meeting on Thursday. However, it noted that the digital infrastructure supporting Pharmacy First, included in the £645 million fresh funding for community pharmacy, will require additional time for implementation. "Delivery remains challenging due to changes needed in digital infrastructure, and we are working with suppliers to support January implementation," NHSE said. "A public campaign is planned for 2024." The Pharmacy First service allows pharmacists to supply prescription-only medicines for seven common health conditions (sinusitis, sore throat, earache, infected insect bite, impetigo, shingles, and uncomplicated urinary tract infections in women), eliminating the need for a GP visit. Meanwhile, NHSE is leveraging the widespread accessibility of pharmacies by expanding blood pressure monitoring and introducing direct prescribing of clinically safe oral contraceptives-an initiative that has been well-received.

In partnership with the pharmaceutical company Boehringer Ingelheim, Leeds Teaching Hospitals Trust (LTHT) has recently established an innovative cardiometabolic clinic. The clinic focuses on reducing cardiovascular risk in people with diabetes who have recently been discharged from LTHT following a heart attack. It is delivered jointly by the cardiology department at Leeds General Infirmary and the diabetes services at the Trust. This is a patient-centred approach to reducing that risk, with pharmacist-delivered clinics scheduled for six to eight weeks after the heart attack. Stephen Wheatcroft, Professor of Cardiometabolic Medicine and Consultant Cardiologist at LTHT, said: "This is an exciting and innovative development, one of the first in the country. Previously, Type 2 diabetic patients presenting with heart issues would have been treated by two separate specialty teams. This is the first time there has been a specific clinic combining the cardiac and diabetes team working together. "We aim to reduce the risk for patients, with earlier multidisciplinary hospital care, to help discharged patients achieve better diabetes control, through improved medication support and optimisation, reducing the need for further treatment and future hospital stays. Overall, it will mean a better patient experience, with improved monitoring and information about treatment options, along with a reduction in waiting times for review in a specialist clinic."

The world's first human challenge trial in which volunteers were deliberately exposed to Covid-19 to advance research into the disease was found to be safe in healthy young adults, one of the companies running the study said on Wednesday. The data supports the safety of this model which could theoretically provide a "plug and play" platform for testing therapies and vaccines using the original Covid-19 strain as well as variants of the virus, Open Orphan, which carried out the study, said in a statement. Open Orphan is running the project, launched a year ago, with Imperial College London, the UK government's vaccines task force and the clinical company  hVIVO. The trial infected 36 healthy male and female volunteers aged 18-29 years with the original SARS-CoV-2 strain of the virus and closely monitored them in a controlled quarantined setting. They will be followed up for 12 months after discharge from the quarantine facility.

Britain has approved Novavax's Covid-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday (February 3), bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant. The vaccine, Nuvaxovid, was approved as a first and second dose as it met the required safety, quality and effectiveness standards, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement. The British approval for Nuvaxovid comes days after the drugmaker filed for US authorisation of the vaccine following months of struggles with development and manufacturing problems, and follows a German backing earlier in the day. "We are continuing our vital safety work in monitoring the use of all Covid-19 vaccines, to ensure that their benefits in protecting people against Covid-19 disease continue to outweigh any risks," MHRA chief executive June Raine said.

Two new subvariants of Omicron - BA.4 and BA.5 - are spreading much faster than other corovanirus variants in Europe, which could lead to more hospitalisations and deaths as they become dominant, the EU's disease prevention agency said on Monday (June 13). Most EU countries have so far detected low rates of the two subgroups. But in countries where the proportion has risen - such as Portugal, where BA.5 accounted for 87 per cent of cases by May 30 - there have been surges in overall cases, according to the European Centre for Disease Prevention and Control (ECDC). The two sublineages were added to the World Health Organization's monitoring list in March and have also been designated as variants of concern by the ECDC. Variants BA.4 and BA.5 do not appear to carry a higher risk of severe disease than other forms of Omicron.But an increase in case numbers from higher transmission rates risks leading to an increase in hospitalisations and deaths, the agency said. "The growth advantage reported for BA.4 and BA.5 suggest that these variants will become dominant," ECDC said in a statement on its website.

Atorvastatin was the most dispensed drug in England in 2021/22 with 53.4 million items, revealed the annual Prescription Cost Analysis (PCA) published by NHS Business Services Authority. According to the official statistics, Apixaban (an anticoagulant) was the drug with the highest cost of £401 million. The statistics revealed that the cost of prescription items dispensed in the community in England was £9.69 billion, a 0.87 per cent increase of £83.7 million from £9.61 billion in 2020/21. "The number of prescription items dispensed in the community in England was 1.14 billion, a 2.58 per cent increase of 28.7 million items from 1.11 billion in 2020/21." FreeStyle Libre 2 Sensor kit (a glucose monitoring system) was the presentation with the largest absolute increase in cost between 2020/21 and 2021/22 of £69.8 million, from £2.84 million to £72.6 million.

Governments should invest in vaccines for all strains of influenza virus that exist in the animal kingdom as an insurance policy in case of an outbreak in humans, the incoming chief scientist at the World Health Organization said on Monday (Feb. 20). Countries ranging from the United States and Britain to France and Japan have suffered record losses of poultry in outbreaks of avian flu in the past year. The recent spread to mammals of H5N1 - commonly known as bird flu - needed to be monitored, but the risk to humans remained low, the WHO said earlier this month. Incoming WHO chief scientist Jeremy Farrar said he would like to see the pharmaceutical industry at least conduct some clinical trials for all influenza strains such that the world would not have to start from scratch to initiate global manufacturing should the need arise. "My concern that we're in slow motion watching something which may never happen," he added in a media briefing. "But if it were to happen, would we look back on what we're doing at the moment and say, why didn't we do more?"

Working conditions in pharmacies have worsened in 2021, the annual Safer Pharmacies Survey conducted by the Pharmacists' Defence Association (PDA) revealed, highlighting the challenging and unsafe environments that some pharmacists are working in. The survey asks pharmacists across all areas of practice about their experiences of key safety measures in the workplace. Since the launch of the Safer Pharmacies Charter in 2017, PDA's annual surveys have monitored their feedback against the Charter's commitments, which covers seven basic areas as standard practice for pharmacy work. The commitments are No Self-Checking, Safe Staffing, Access to a Pharmacist, Adequate Rest, Respect for Professional Judgment, Raising Concerns and Physical Safety. The survey revealed that eight out of 10 feel unsafe at work as violence and abuse still remain areas of concerns in pharmacy.

The new Flat Fee payment to roll out in April 2023 to all pharmacy contractors who dispense at least 101 items a month, up to a national total of £70m on an annual basis. "The value of the Flat Fee payment has now been determined at £533 per month and will be introduced in the April 2023 Drug Tariff," said the Pharmaceutical Services Negotiating Committee (PSNC). "As with all payments, the Flat Fee payments are subject to change throughout the year depending on the overall level of funding delivery to Community Pharmacies. This will be carefully monitored by PSNC and DHSC, and any funding changes will be communicated to pharmacy contractors as soon as they are known," said PSNC.

Reacting to recommendations from a UK-first independent review, the Department of Health and Social Care (DHSC) has outlined action to tackle potential bias in the design and use of medical devices. Professor Dame Margaret Whitehead, professor of public health at the University of Liverpool, was appointed to lead the review, which focused on three areas - optical devices such as pulse oximeters, AI-enabled devices, and polygenic risk scores (PRS) in genomics. The DHSC commissioned the medical devices review after concerns were raised that pulse oximeters - widely used during the COVID-19 pandemic to monitor blood oxygen levels - were not as accurate for patients with darker skin tones. There were worries that this could cause delays in treatment if dangerously low oxygen levels in such patients were missed. However, no evidence was found from NHS studies indicating that this differing performance had an impact on patient care. Accepting the report's conclusions, the DHSC has committed to several actions, such as ensuring the safe use of pulse oximeter devices across a range of skin tones within the NHS and eliminating racial bias from data sets employed in clinical studies.

The National Health Services England (NHSE) is poised to revolutionise diabetes management with the introduction of the 'artificial pancreas', also known as the Hybrid Closed Loop system, to treat type 1 diabetes. This pioneering initiative, endorsed by the National Institute of Health Care and Excellence (NICE), represents a global first in healthcare innovation. With 269,095 individuals grappling with type 1 diabetes in England, the Hybrid Closed Loop system is set to cater to tens of thousands of children and adults across the nation. This cutting-edge device operates by seamlessly monitoring blood glucose levels and autonomously adjusting insulin dosage through a pump, by eliminating the need for regular insulin injections. Furthermore, it holds the promise of averting life-threatening hypoglycaemic and hyperglycaemia episodes, mitigating significant risks associated with the condition. To facilitate the identification of beneficiaries, NHSE has allocated a substantial sum of £2.5 million, ensuring that those who could benefit from this innovative solution receive the necessary support.

In a recent announcement, the British supermarket chain, Asda has launched its first online prescription service becoming the first self-serving shop to offer prescribed medicine supply at the doorsteps through its latest healthcare accessibility venture. The NHS certified online pharmacy service, Asda Online Pharmacy, is set to offer patients a digital platform designed to simplify the prescription process for patients, offering the convenience of online management and home delivery with their partnership with Pharmacy2U. Effective immediately, new patients can register for an account on the platform via pharmacy.asda.com. Once registered, they gain access to a seamless prescription ordering system that facilitates home delivery, along with the ability to monitor the progress of their orders. Prescriptions submitted through Asda Online Pharmacy will undergo rigorous scrutiny by qualified pharmacists before being dispatched directly to patients' doorsteps, all without any additional charges.

Seven NHS trusts in England are set to begin trials of new wireless technologies to help improve patient care and strengthen connectivity in A&Es and ambulance bays. They have been awarded around £1 million as part of NHS England's Wireless Trials programme, which aims to leverage advanced wireless technologies to enhance patient care and experiences while freeing up more staff time. Manchester University NHS Foundation Trust will introduce an innovative approach of combining satellite and cloud-based wireless solutions to enhance connectivity across its 10 hospital sites and wider community services. At Mid Cheshire and Princess Alexandra Hospital NHS trusts, wireless trackers will be installed on medical equipment and hospital beds. This will allow real-time monitoring and location tracking, enabling easy accessibility for staff to locate necessary items promptly.

The British Generic Manufacturers Association (BGMA) on Monday alerted the Health and Social Care Committee that medicines shortages have increased and are "around double what they were a year ago." BGMA chief executive Mark Samuels told the committee that they have been highlighting the medicine shortage risk to ministers since July 2021 and the association is "very concerned" about the current situation. "We've been monitoring it for several years now, and as you saw in the written evidence, shortages have increased. They're around double what they were a year ago. We have them at 101 shortages in February this year," said Samuels. Dr Rick Greville, director of distribution and supply at the Association of the British Pharmaceutical Industry (ABPI), highlighted that the problem of drug shortages in the UK is a "long-standing issue" and the scarcity of certain medications "continues to be challenging".

Optifast Shakes Reviews : OPTIFAST products are distributed through weight loss clinics nationwide and are not available for retail sale. OPTIFAST is distributed by trained healthcare professionals to patients who have been through an initial screening process and participate in an ongoing medically monitored OPTIFAST program Optifast Shakes Reviews.

Optifast Shakes Reviews : OPTIFAST products are distributed through weight loss clinics nationwide and are not available for retail sale. OPTIFAST is distributed by trained healthcare professionals to patients who have been through an initial screening process and participate in an ongoing medically monitored OPTIFAST program.